We conducted a serial cross-sectional study to evaluate the use of PET imaging among commercial insurance beneficiaries with prostate cancer using administrative claims from deidentified Blue Cross ...
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced results ...
Investigators developed and validated new PSMA-PET-based nomograms for prognostication across prostate cancer stages to help ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
On track to share data from first two dose levels in 2H 2026Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative ...
Some high-grade prostate cancers, such as intraductal carcinoma of the prostate, are not clearly visible on PSMA PET. For patients with intraductal carcinoma of the prostate (IDC-P), prostate-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results